Syndax Pharmaceuticals, Inc.
PosiFunda Ratios Only on PositoAI
PositoAI's own ratios from Syndax Pharmaceuticals, Inc.'s yearly results (2022–2025), compared with Healthcare companies in United States. Tap ? on any ratio for what it means.
What stands out
- Debt Due Cover Ratio: Operating cash was negative last year, while some debt falls due within a year. Lower than 97% of Healthcare companies in United States.
Where $100 of sales goes
Latest year (Dec 2025). Taxes and other income are not shown, so the parts need not add up to 100.
Cash quality
Profit Cash Ratio
—Loss-making or profit too small
Over the last 3 years profit was a loss or under 2% of sales, so cash per 100 of profit is not meaningful.
Self-Funding Ratio
—Data incomplete
Cash Locked Ratio
—Data incomplete
Growth quality
Steadiness Ratio
2/3 · 1/3Sales grew in 2 of the last 3 years; profit grew in 1 of 3.
Steadier than 50% of Healthcare companies in United States.
Growth Efficiency Ratio
—Data incomplete
Asset Productivity Ratio
—Data incomplete
Balance-sheet strength
Debt Due Cover Ratio
-684.3×Operating cash was negative last year, while some debt falls due within a year.
Lower than 97% of Healthcare companies in United States.
Cash Cushion Ratio
+6%Cash, after subtracting all debt, equals 6% of its market value (net cash).
Lower than 56% of Healthcare companies in United States.
Tangible Assets Ratio
—Data incomplete
Tangible Net Worth Ratio
—Data incomplete
Shareholders
Standard fundamentals
P/E, P/B, ROE, debt, growth and more (13)
Syndax Pharmaceuticals, Inc. made a loss over the last year. Syndax Pharmaceuticals, Inc. owes $0.98 for every $1 it owns. Syndax Pharmaceuticals, Inc. made a loss in each of the last two years.
Compared with Healthcare companies in United States · latest annual results Dec 2025.
P/E ratio
LossSyndax Pharmaceuticals, Inc. made a loss over the last year, so its P/E ratio is not meaningful.
P/B ratio
80.25The share price is 80.25 times Syndax Pharmaceuticals, Inc.'s book value per share, higher than almost all Healthcare companies in United States.
Market cap
$1.2 BThe total market value of all of Syndax Pharmaceuticals, Inc.'s shares at today's price (share price × number of shares), larger than 66% of Healthcare companies in United States. PosiCap size class: Meso Cap.
Net worth (book value)
$15 MWhat Syndax Pharmaceuticals, Inc. would have left on paper if it sold everything it owns and paid everything it owes, from its latest balance sheet (30 Jun 2026).
Book value per share
$0.17Net worth divided by the number of shares. The share price of $13.57 is 80.3 times this, which is the P/B above.
Return on equity (ROE)
-255.9%Syndax Pharmaceuticals, Inc. lost 255.9% of its shareholders' money over the last year, lower than 88% of Healthcare companies in United States.
Owes vs Owns
0.98×Syndax Pharmaceuticals, Inc. owes $0.98 for every $1 it owns (high), higher than 86% of Healthcare companies in United States.
Dividend yield
NoneSyndax Pharmaceuticals, Inc. does not currently pay a dividend.
Revenue growth
+628%Revenue rose 628% in the year to Dec 2025.
Profit growth
LossSyndax Pharmaceuticals, Inc. made a loss in each of the last two years.
Profit margin
-165.6%Syndax Pharmaceuticals, Inc. lost $166 for every $100 of revenue.
Interest cover
Not coveredSyndax Pharmaceuticals, Inc.'s operating profit did not cover its interest costs in the year to Dec 2025.
Cash vs debt
Net cashSyndax Pharmaceuticals, Inc. held $68 M more cash than debt (net cash) at Dec 2025.
Questions
How is P/B calculated on PositoAI?
P/B is market cap divided by net worth from the latest balance sheet. For Syndax Pharmaceuticals, Inc.: $1.2 B ÷ $15 M (30 Jun 2026) = 80.3.
What is Syndax Pharmaceuticals, Inc.'s return on equity?
Syndax Pharmaceuticals, Inc. lost 255.9% of its shareholders' money over the last year, lower than 88% of Healthcare companies in United States.
How much does Syndax Pharmaceuticals, Inc. owe compared with what it owns?
Syndax Pharmaceuticals, Inc. owes $0.98 for every $1 it owns (high), higher than 86% of Healthcare companies in United States.
Does Syndax Pharmaceuticals, Inc. pay a dividend?
No. Syndax Pharmaceuticals, Inc. does not currently pay a dividend.
Is Syndax Pharmaceuticals, Inc.'s revenue growing?
Revenue rose 628% in the year to Dec 2025.
Figures from the company's yearly results and PositoAI's own data. Full tables are on the Go Deep tab. What each figure means. PositoAI is for research and education only and is not investment advice.